Stay updated on Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial page.

Latest updates to the Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedAn NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence,” and the site revision label changes from v3.7.1 to v3.7.2. The study page itself continues to display a 403 error.SummaryDifference1%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe ClinicalTrials.gov footer revision identifier changed from v3.7.0 to v3.7.1; the study page continues to display a 403 error.SummaryDifference0.2%

- Check40 days agoChange DetectedThe page now renders a 403 Forbidden error instead of the study record content. The detailed study information and navigation have been replaced by an error page.SummaryDifference20%

- Check47 days agoChange DetectedRevision updated from v3.6.6 to v3.7.0 on the page, reflecting a site-wide upgrade. This change does not modify the study-specific content or data shown on the page.SummaryDifference0.1%

- Check61 days agoChange DetectedThe page revision label has been updated to v3.6.6, indicating a minor platform update. There are no changes to study details or visible content.SummaryDifference0.1%

- Check82 days agoChange DetectedThe page now shows Revision: v3.6.5, replacing v3.6.4. This indicates a new software release of the site platform.SummaryDifference0.1%

Stay in the know with updates to Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib Pembrolizumab Combo in Advanced Melanoma Clinical Trial page.